FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Semantic Scholar
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer | Scientific Reports
Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval | MDedge Hematology and Oncology
Advanced MSI-H/dMMR Colorectal Cancer | KEYTRUDA® (pembrolizumab) | Patients
Pembrolizumab prolongs PFS vs. chemotherapy for certain patients with colorectal cancer
Pembrolizumab Shows Continued PFS Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
Approval of pembrolizumab (MSI-H/dMMR) and considerations for site-agnostic development of drugs in oncology
Keytruda Granted Full Approval for MSI-H/dMMR Solid Tumors - Specialty Pharmacy Continuum
First-Line Pembrolizumab Versus Chemotherapy in Patients
Practice-Changing KEYNOTE-177 Results Support First-Line Pembrolizumab Monotherapy for MSI-H mCRC
Keytruda Granted Full Approval for Advanced MSI-H or dMMR Solid Tumors - Cancer Therapy Advisor
Keytruda doubled survival in advanced colon cancer compared to chemo' < Pharma < Article - KBR
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study - Annals of Oncology
Pembrolizumab for Advanced MSI-H/dMMR Cancers
KEYNOTE-177 - Advanced MSI-H/dMMR Colorectal Cancer (CRC) - HCP
Colorectal Cancer Alliance
ESMO 2022: Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H)
considerations in development of pembrolizumab in MSI-H Cancers
Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication - ILCN.org (ILCN/WCLC)
Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers | SpringerLink
Approval of pembrolizumab (MSI-H/dMMR) and considerations for site-agnostic development of drugs in oncology
Merck's KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors | Business Wire
Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With Specific DNA Mutations | ASCO
